Bortezomib (PS-341)

For research use only.

Catalog No.S1013 Synonyms: LDP-341, MLM341

496 publications

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 91 In stock
USD 70 In stock
USD 127 In stock
USD 270 In stock
USD 670 In stock
USD 1370 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Bortezomib (PS-341) has been cited by 496 publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MUjDfZRwfG:6aXOgRZN{[Xl? MXm1NEDPxE1? MYS0PEBp MVPEUXNQ NVfrflNNU2mubIOgZ4VtdHNiYomgcY9z\SC2aHHuJFk6LQ>? NXi1R49YOTB2OUm2OFM>
OVCA 429 NV;yUJZQTnWwY4Tpc44hSXO|YYm= NVvXdGlEOzByIH7N MY[0PEBp M3H5eWROW09? Moq5SIl{enWydIOgbY51[WO2IH31cJRq[2WubIXsZZIhfHWvb4Kgd5Bp\XKxaXTz NIT4b4wyODl7OUe2Oi=>
RPMI8226 MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELhVnYyODBibl2= M2TLO|Q5KGh? MmjsSG1UVw>? NXrtTlBvUUN3ME2zNEBvVQ>? NGLpS4wyOTNyNkS4PS=>
Dox40 NFXyeJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL5NVAxKG6P MoHWOFghcA>? NI\sTmhFVVOR MomyTWM2OD12MDDuUS=> MVmxNVMxPjR6OR?=
MR20 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHCdYoyODBibl2= M1\tWlQ5KGh? NEDvW2tFVVOR Mne4TWM2OD1{MDDuUS=> MYSxNVMxPjR6OR?=
LR5 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVWxNFAhdk1? MX[0PEBp NITkc2NFVVOR MonJTWM2OD1{MDDuUS=> MX:xNVMxPjR6OR?=
U266 NFXhVnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnUUI4yODBibl2= Moe4OFghcA>? M2L4O2ROW09? MoLsTWM2OD1|IH7N M1;ZN|EyOzB4NEi5
IM-9 NI[1NI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz0NVAxKG6P MmDlOFghcA>? NEjhVZNFVVOR MkTQTWM2OD14IH7N NW\oeHVbOTF|ME[0PFk>
Hs Sultan MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTlNVAxKG6P NH20[Yw1QCCq NU\hNmJSTE2VTx?= MVPJR|UxRTJyIH7N MUOxNVMxPjR6OR?=
PAM-LY2 M3XSdWZ2dmO2aX;uJGF{e2G7 Mo\ENVAxKG6P M1nTOVEzKGh? NEC4[phFVVOR NUfFfFVqUW6qaXLpeJMhVkZvzsrCJIFkfGm4YYTpc44> MX2xNVM2ODlzMx?=
PAM 212 M170R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7wNVAxKG6P MmLoO|IhcA>? M3nEN2ROW09? MkS4TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NX\wO2VKOTF|NUC5NVM>
PAM-LY2 NFGzcZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHq0d4YyODBibl2= M2HUd|czKGh? M1T1R2ROW09? NUDqZ2N7UW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= NXTYNZE3OTF|NUC5NVM>
B4B8 M3L6NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nwTVExOCCwTR?= M3jyOVczKGh? NVn1dnZRTE2VTx?= NI\ROnZKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= M4fCelEyOzVyOUGz
B7E3 NVnZTmR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXXS2ZZOTByIH7N NEHxPZc4OiCq NIfuVIFFVVOR MV7Jcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NIC0R5UyOTN3MEmxNy=>
UM-SCC-9 NV7MV3JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqxNFAhdk1? Mn[2O|IhcA>? M1rGemROW09? NWHPNnpiUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= NHr5UpAyOTN3MEmxNy=>
UM-SCC-11B M3XIRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLoNVAxKG6P M2K0UFczKGh? NUP4ZoRlTE2VTx?= MmLvTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NVrhRpBOOTF|NUC5NVM>
H460 MW\GeY5kfGmxbjDBd5NigQ>? M{O4OVExKM7:TR?= NGXsXGozPCCq NIfLbIRFVVOR M2LpPGlv\HWlZYOgRoNtNTJicHjvd5Bpd3K7bHH0bY9vKGGwZDDjcIVifmGpZTDjc5Jz\WyjdHXkJJdqfGhiR{KtUUBxcGG|ZTDhdpJme3R? MUWxNlQ6OjFzNx?=
U266 NXvHd5JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnK3OVAxKG6pL33s MlXwOFghcA>? NYfI[nhjTE2VTx?= M4e1PWlvcGmkaYTzJINmdGxiZ4Lve5Rp NU\yNIwxOTJ4M{G2NVk>
ARH77 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUP5PYc{PTByIH7nM41t M{PKO|Q5KGh? MYLEUXNQ M4DGSWlvcGmkaYTzJINmdGxiZ4Lve5Rp Mn:wNVI3OzF4MUm=
WAD-1 NU\MU|FNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Trd|UxOCCwZz;tcC=> NW\YPZlnPDhiaB?= NHLWSXdFVVOR M2HiN2lvcGmkaYTzJINmdGxiZ4Lve5Rp NXK5R3Z4OTJ4M{G2NVk>
U266/LR7 M1zjNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\VZVUxOCCwZz;tcC=> MU[0PEBp NUDicmdWTE2VTx?= NGXrbXpKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NXrpTYszOTJ4M{G2NVk>
U266/dox4 MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7yV5FvPTByIH7nM41t M33WV|Q5KGh? MYjEUXNQ MW\Jcohq[mm2czDj[YxtKGe{b4f0bC=> NGW5bm0yOjZ|MU[xPS=>
RPMI8226/LR5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFGzOFY2ODBibnevcYw> NWn4T|I6PDhiaB?= NUDSOXRbTE2VTx?= NV\ldGpUUW6qaXLpeJMh[2WubDDndo94fGh? MXSxNlY{OTZzOR?=
H460 NXjL[mZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLyW3J4OTBizszN M1PpNFczKGh? M2f6SmROW09? MX3JR|UxRTFyMDDuUS=> MlXsNVI3OzF4MkC=
H358 M{\1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXiwfVVROTBizszN MknyO|IhcA>? MUPEUXNQ NFvRcWdKSzVyPUewJI5O M{jqUFEzPjNzNkKw
H322 M2LN[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjZbJgyOCEQvF2= NI\Fd3E4OiCq Mn\tSG1UVw>? M4rYS2lEPTB;NkKwJI5O NV23eJk4OTJ4M{G2NlA>
H460 MYHGeY5kfGmxbjDBd5NigQ>? MlrGNVAxKG6P NIjkO2kzPCCq MX;EUXNQ MnXLTY5lfWOnczDHNk1ONXCqYYPlJIFzemW|dDDhcoQhfHWkdXzpckBie3OnbXLsfU1lcXOjc4PlcYJtgQ>? MUmxNlY{OTZ{MB?=
LNCap-Pro5 NYPZbYlvTnWwY4Tpc44hSXO|YYm= M4HtfFEh|ryP NIH2V|E1KGh? M{PMe2ROW09? NGrjdFFUfGGkaXzpfoV{KHB3Mx?= MYCxOFYyOjV|Mh?=
T29 MVPBdI9xfG:|aYOgRZN{[Xl? NF7tRVI2OCCwTR?= MVW0PEBpKA>? NGDHbVJFVVOR M4DDbGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M3ftR|E3Pzd6MUe5
T29Kt1 MX7BdI9xfG:|aYOgRZN{[Xl? M17KS|UxKG6P M{HaclQ5KGhi NUDpdXBCTE2VTx?= NHP0U5NKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MUCxOlc4QDF5OR?=
HCT116 NIr2WVFCeG:ydH;zbZMhSXO|YYm= NUjy[Vh6PTBibl2= Mo\OOFghcCB? NVTmWGpJTE2VTx?= M1LVVGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? Mkm1NVY4PzhzN{m=
HKe-3 NWLrPXhtSXCxcITvd4l{KEG|c3H5 MljzOVAhdk1? NIHGU5g1QCCqIB?= M3uzR2ROW09? MULJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NFnWZ3EyPjd5OEG3PS=>
NB-1691 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nUTlEh|ryP MXe3NkBp NWfE[o93UW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEWl M4C2flE4Pjh7Nki0
CHLA-255 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWexJO69VQ>? NUf5Ro1PPzJiaB?= MXfJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOiV? M4\LTVE4Pjh7Nki0
SK-N-AS NUjXfFRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX2xJO69VQ>? NEWzTVU4OiCq MYfJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOTBn NVXSZZlzOTd4OEm2PFQ>
NB-1691 NHvqSG9HfW6ldHnvckBCe3OjeR?= MWexNEBvVQ>? M2H1N|I1KGh? MorZV4lodmmoaXPhcpRtgSC{ZXT1Z4V{KGOnbHzzJIlvKHSqZTDHNE9IOSCyaHHz[S=> Mme3NVc3QDl4OES=
CHLA-255 Mn;DSpVv[3Srb36gRZN{[Xl? NVjBNFIzOTBibl2= NV7Cb3ViOjRiaB?= NXy2[VY5VW:mZYP0cJkhemWmdXPld{Bk\WyuczDpckB1cGViR{CvS|EheGijc3W= NELpcFIyPzZ6OU[4OC=>
RPMI 8226 MUPGeY5kfGmxbjDBd5NigQ>? M1myPFIxKG6P MU[4JIg> NYnSXFdZW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? M121clE6PDN4MEWw
MM.1S MVTGeY5kfGmxbjDBd5NigQ>? MXSyNEBvVQ>? NHmyfYs5KGh? MojyV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> NF;GUo4yQTR|NkC1NC=>
U266 NEfzb5dHfW6ldHnvckBCe3OjeR?= MmG1NlAhdk1? M1PkNVghcA>? Ml7LV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> NEPtV2MyQTR|NkC1NC=>
OPM1 MWjGeY5kfGmxbjDBd5NigQ>? MkHONlAhdk1? M2rBRVghcA>? Mn\XV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> MUSxPVQ{PjB3MB?=
INA6 NXv3[VBjTnWwY4Tpc44hSXO|YYm= NUGyXHpCOjBibl2= MUS4JIg> M1Xh[HNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MmPLNVk1OzZyNUC=
OPM2 NH\jXZZHfW6ldHnvckBCe3OjeR?= NELhboUzOCCwTR?= M{jvN|ghcA>? MnvBV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> MWmxPVQ{PjB3MB?=
RPMI 8226 MnH3SpVv[3Srb36gRZN{[Xl? MWmyNEBvVQ>? NEH0THU5KGh? NVjGSpVTUW6mdXPld{BFVkFic4nueIhme2m| MmrZNVk1OzZyNUC=
BaF/3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjPU2RpOTByIH7N M{PQSVQ5KGh? MkPvTWM2OD14LkKgcm0> MYOyNFMxPTZ7Mh?=
BaF/3-p210 M4fnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfGWWdzOTByIH7N NVzFe5dwPDhiaB?= NGXkdohKSzVyPUSuO{BvVQ>? M1TR[|IxOzB3Nkmy
TCC-S M2jjeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4The|ExOCCwTR?= NYT0Tm5GPDhiaB?= NIHMT2NKSzVyPUKuPEBvVQ>? NGXUeJgzODNyNU[5Ni=>
BaF/3 NIn3TFNHfW6ldHnvckBCe3OjeR?= MljGOkBvVQ>? NVj5VoRnPDhiaB?= MWXJcoR2[2W|IHGg[5Jm[XRiR{GgZ4VtdC2leXPs[UBienKnc4S= NE\De3MzODNyNU[5Ni=>
BaF/3-p210 NF\afmNHfW6ldHnvckBCe3OjeR?= MojlOkBvVQ>? NHvwZ|k1QCCq M2DxXGlv\HWlZYOgZUB{dGmpaISgS|Eh[2WubD3jfYNt\SCjcoLld5Q> MViyNFMxPTZ7Mh?=
BaF/3-p210 Mli4SpVv[3Srb36gRZN{[Xl? NE\heJQ3KG6P NWnKbndVOjRiaB?= M2XDSnJm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBidmRidHjlJIFkfGm4aYT5JI9nKFKk NYn5fZVpOjB|MEW2PVI>
Raji NWn3dXlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;oXIwyKM7:TR?= M3jHUVI1KGh? Ml;KVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi M3u2UVIyOTdyOUi4
LCL-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVqxJO69VQ>? NXLxTnllOjRiaB?= NIfGSGRT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MXOyNVE4ODl6OB?=
LCL-2 NEjsWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jxSFEh|ryP NULFfI44OjRiaB?= NYfPXGZCWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MoXHNlEyPzB7OEi=
BJAB NXLvblI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofmNUDPxE1? NUjsSZhbOjRiaB?= NHO2bFVT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= M1\lWVIyOTdyOUi4
SNT-13 Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fpblEh|ryP NFT3[W8zPCCq MWjS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NVzwc4lyOjFzN{C5PFg>
SNT-16 M3LBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jaeFEh|ryP NH2zZmYzPCCq M1ezZXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MonxNlEyPzB7OEi=
Jurkat NFy2b2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjzUXgyKM7:TR?= NG\oSVAzPCCq M1j4WnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NY\rS3ZHOjFzN{C5PFg>
KAI-3 MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mly1NUDPxE1? NVTuV3l6OjRiaB?= NIrhe2dT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= M1:zb|IyOTdyOUi4
SNK-6 NHLqOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVGxJO69VQ>? MUmyOEBp MoXhVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NXGyW3lLOjFzN{C5PFg>
KHYG-1 MlfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXyxJO69VQ>? MoeyNlQhcA>? M1;HUXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= M3fJblIyOTdyOUi4
SNT-16 MlPnRZBweHSxc3nzJGF{e2G7 MVqxJO69VQ>? NUD4XJdDPiCq MYjJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NIj0NW8zOTF5MEm4PC=>
Jurkat NHXNVWVCeG:ydH;zbZMhSXO|YYm= M{Dy[|Eh|ryP M3XzZ|YhcA>? NVXHRlJbUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MoPJNlEyPzB7OEi=
KAI-3 NELaNVlCeG:ydH;zbZMhSXO|YYm= NXLSOmt5OSEQvF2= NY\MS2g2PiCq M3rqN2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MlHVNlEyPzB7OEi=
KHYG-1 NXHWeXNZSXCxcITvd4l{KEG|c3H5 Ml:3NUDPxE1? M1HMNFYhcA>? NGPrT5lKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MW[yNVE4ODl6OB?=
SNT-13 M3u2WmFvfGm4aYLhcEBCe3OjeR?= MVixJO69VQ>? MnznNlQhcA>? NILVT4xKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? MXiyNVE4ODl6OB?=
SNT-16 MmDuRY51cX[rcnHsJGF{e2G7 NE\CRosyKM7:TR?= NYroVlNmOjRiaB?= M1HZbmlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? MmK1NlEyPzB7OEi=
KAI-3 NXnXemd2SW62aY\pdoFtKEG|c3H5 MY[xJO69VQ>? MXKyOEBp MYnJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> MW[yNVE4ODl6OB?=
SNK-6 NFrhUFlCdnSrdnnyZYwhSXO|YYm= M2rwbFEh|ryP MoDsNlQhcA>? MY\JcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> NIf5PWYzOTF5MEm4PC=>
RAW 264.7 NXfGZXRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUixNFAhdk1? NWfhVGhSPDhiaB?= NFPNfm9T\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= Ml;QNlI1OjdzNUS=
A375 MV7BdI9xfG:|aYOgRZN{[Xl? MmHzNVAhdk1? MkK0NlQhcA>? MYrJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MYiyN|A4QTB6Mx?=
BLM NEKyd4RCeG:ydH;zbZMhSXO|YYm= NEXG[I8yOCCwTR?= MXuyOEBp MlXZTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M1jh[VI{ODd7MEiz
A375 NH7xXXdCfXSxcHjh[5khSXO|YYm= MUKxNEBvVQ>? MlHwNVIhcA>? MnK5TY5lfWOnczDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO= MorONlMxPzlyOEO=
BLM NVPNemZxSXW2b4DoZYd6KEG|c3H5 Mn;iNVAhdk1? M{W0SlEzKGh? NIXDZ2tKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> NYDJTIFqOjNyN{mwPFM>
H1299 MWrBdI9xfG:|aYOgRZN{[Xl? M3vxUVgxKG6P MmPsNlQhcA>? M3zITWROW09? NV6xfJFuW2Wwc3n0bZpmeyCQU1PMR{Bk\WyuczD0c{BOW0NvZHXybZZm\CCrQ{mtbY5lfWOnZDDhdI9xfG:|aYO= NYDoe5J[OjV|MkO2PVM>
Hut-78 NE\ubWVHfW6ldHnvckBCe3OjeR?= Mof3NVAxKG6P NIPXNXMzPCCq MX7EUXNQ MV\Ec5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVExKGW6cILld5Nqd25? NGr0W3QzPTZ6MUOzOS=>
H9 MYPGeY5kfGmxbjDBd5NigQ>? NV;qV25ROTByIH7N MUiyOEBp M4n3O2ROW09? MXTEc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVEyKGW6cILld5Nqd25? M4fhVlI2PjhzM{O1
HH NH\KeIhHfW6ldHnvckBCe3OjeR?= MkLDNVAxKG6P M3fjbVI1KGh? NX3pWZN4TE2VTx?= NEjRN3pld3ewcnXneYxifGW|IGTHSk3PujFiYX7kJGlNNTF{IHX4dJJme3Orb36= MXGyOVY5OTN|NR?=
Hut-78 MVPNbYdz[XSrb36gRZN{[Xl? M2fPeVExOCCwTR?= NGrPc3EzPCCq Ml\hSG1UVw>? M3zvUnJm\HWlZYOgZ4VtdCCvaXfyZZRqd25iYomgPFDjiJN7MDW= NXPYbZBKOjV4OEGzN|U>
HH MoK0UYloemG2aX;uJGF{e2G7 MWexNFAhdk1? M2mxfFI1KGh? M2jCcGROW09? MojkVoVlfWOnczDj[YxtKG2rZ4LheIlwdiCkeTC4NQKBmzlzJR?= NEW2XIIzPTZ6MUOzOS=>
U937 MWPGeY5kfGmxbjDBd5NigQ>? M2HhRVExOCCwTR?= M3riNFYhcA>? M3LneGlv\HWlZYOgTWwuQCCneIDy[ZN{cW:wIHnuJGxRWy2|dHnteYxifGWmIGW5N|chdWGlcn;wbIFo\XN? NF73WnozPTd7MUS3Oy=>
human PBMC MlfkSpVv[3Srb36gRZN{[Xl? MVyxNFAhdk1? MXuyOEBp NHjLN4xKdmS3Y3XzJGlNNThicnXs[YF{\Q>? MlTMNlU4QTF2N{e=
ES6 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zRfWlEPTB;MD6wNFIyKG6P M2rLTnNCVkeHUh?=
SK-UT-1 M{jIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPQVIdQUUN3ME2wMlE3OyCwTR?= MY\TRW5ITVJ?
SH-4 MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwMUezJI5O NH\lb2VUSU6JRWK=
TE-9 NH7aXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXtTWM2OD1yLkG4NkBvVQ>? NGLxXGpUSU6JRWK=
A253 MnmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnyXIhKSzVyPUCuNlA5KG6P NIC3U5ZUSU6JRWK=
no-10 NF20SXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jCVGlEPTB;MD6yNUBvVQ>? NIPFRZhUSU6JRWK=
MMAC-SF NELwNVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF33SnFKSzVyPUCuNlE3KG6P MXLTRW5ITVJ?
A101D M3[zV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DHOGlEPTB;MD6yNlUhdk1? NVvBVY1xW0GQR1XS
NTERA-S-cl-D1 MoDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vIPWlEPTB;MD6yOFMhdk1? NUjwZ|ZGW0GQR1XS
8-MG-BA MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwMkWgcm0> NIfO[GxUSU6JRWK=
KNS-42 NFi4UW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Xr[WlEPTB;MD6yOVghdk1? NEHzU41USU6JRWK=
LXF-289 M{fCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPsXYNKSzVyPUCuNlY6KG6P NGjhN5RUSU6JRWK=
OVCAR-4 NVzQNnFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUL4VHlJUUN3ME2wMlI5QSCwTR?= MWLTRW5ITVJ?
LOUCY MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwMkmzJI5O NXHjemNoW0GQR1XS
BB65-RCC Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrlTWM2OD1yLkOwOEBvVQ>? NWXw[5JmW0GQR1XS
D-542MG M3O2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLHcnJuUUN3ME2wMlMzQSCwTR?= MmfwV2FPT0WU
ONS-76 M17rWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwM{Ogcm0> NGHXUpJUSU6JRWK=
BB30-HNC M1TxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjheldKSzVyPUCuN|M2KG6P M1HQUHNCVkeHUh?=
KS-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q0W2lEPTB;MD6zOEBvVQ>? NEXEUVlUSU6JRWK=
A388 NGfIOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;vZmlEPTB;MD6zOVYhdk1? Ml;FV2FPT0WU
ES8 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPnSWdsUUN3ME2wMlQhdk1? NXrRZXV6W0GQR1XS
MZ2-MEL MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwNEC3JI5O MnXzV2FPT0WU
HCC2998 M3LETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jxdWlEPTB;MD60NVIhdk1? M2\6NnNCVkeHUh?=
D-247MG NES0cW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTYTWM2OD1yLkSxN{BvVQ>? M3To[HNCVkeHUh?=
ACN NIL5SJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDhTWM2OD1yLkSxO{BvVQ>? MYPTRW5ITVJ?
LB2518-MEL Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFGwOnJKSzVyPUCuOFI2KG6P NVztU2l2W0GQR1XS
ES1 NX21Z49oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLFSGVPUUN3ME2wMlQ{KG6P MnTWV2FPT0WU
HCE-T MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYew[ndGUUN3ME2wMlQ{QSCwTR?= MWTTRW5ITVJ?
OS-RC-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwNESgcm0> MVTTRW5ITVJ?
MFH-ino MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXuTWM2OD1yLkS0N{BvVQ>? M1SzR3NCVkeHUh?=
OCUB-M NXHTO3Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGS4UXFKSzVyPUCuOFQ4KG6P M2D3d3NCVkeHUh?=
CP66-MEL M37QV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TM[WlEPTB;MD60O|Mhdk1? NWXtbZhSW0GQR1XS
LB771-HNC NFznU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwNEe0JI5O NG\tfWNUSU6JRWK=
DSH1 NXXzeJVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPUTFY6UUN3ME2wMlQ5KG6P Ml3NV2FPT0WU
HUTU-80 NUG3bHNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzyS|lKSzVyPUCuOVM{KG6P NV7HbXg2W0GQR1XS
CESS M2X2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwNUO4JI5O NGPCfppUSU6JRWK=
NCI-H747 MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwNUO5JI5O Mmi2V2FPT0WU
HT-144 NY[2fYpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PCXGlEPTB;MD61O|Yhdk1? NGSzToRUSU6JRWK=
COLO-829 M1GxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4C4e2lEPTB;MD62NVQhdk1? MorIV2FPT0WU
A4-Fuk NXe4W5p1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoG3TWM2OD1yLk[yN{BvVQ>? MV;TRW5ITVJ?
GI-ME-N NEf0O3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\5bIlIUUN3ME2wMlY{PCCwTR?= MV;TRW5ITVJ?
LB831-BLC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGL4Z3ZKSzVyPUCuOlQyKG6P NHnSOI5USU6JRWK=
HOP-62 MmK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP6cFRWUUN3ME2wMlY1PyCwTR?= NX7zWWFrW0GQR1XS
BB49-HNC M3vVfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwNkWyJI5O MVnTRW5ITVJ?
D-336MG MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwNkW3JI5O M{HMNXNCVkeHUh?=
TK10 NUTwVJNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfWOXA{UUN3ME2wMlY4QSCwTR?= NYjNVWhOW0GQR1XS
Ramos-2G6-4C10 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwNkmzJI5O M{jaSHNCVkeHUh?=
LB373-MEL-D NYjiOJVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2i2eWlEPTB;MD63JI5O NFv0O5NUSU6JRWK=
SF126 MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInrWGVKSzVyPUCuO|AyKG6P MX;TRW5ITVJ?
UACC-257 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnG2TWM2OD1yLkexJI5O M3PCenNCVkeHUh?=
KINGS-1 MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwN{KyJI5O NEn5WmpUSU6JRWK=
LS-513 MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGm0WY1KSzVyPUCuO|M6KG6P NHS4eoZUSU6JRWK=
GI-1 NXPpeZVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LrcGlEPTB;MD63OlQhdk1? M1\FNXNCVkeHUh?=
ES7 NHv4bHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwN{[2JI5O NGXYcGtUSU6JRWK=
LB2241-RCC NITzXIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwOEC0JI5O MYPTRW5ITVJ?
D-263MG MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDZRXNZUUN3ME2wMlgxPyCwTR?= M{H3NnNCVkeHUh?=
SW684 NIHHellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYL2Nod[UUN3ME2wMlgzOSCwTR?= Mly5V2FPT0WU
ML-2 NInkNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnpSZF3UUN3ME2wMlgzOSCwTR?= NVi5dndvW0GQR1XS
SK-LMS-1 NVPOeVltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrYTWM2OD1yLki1OEBvVQ>? MUnTRW5ITVJ?
TE-5 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7ZTWM2OD1yLki2OUBvVQ>? MlTGV2FPT0WU
QIMR-WIL MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwOEi5JI5O MofCV2FPT0WU
NCI-H1355 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwOEm1JI5O M4f3dnNCVkeHUh?=
SNB75 NULZ[WFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;KTWM2OD1yLkmxNkBvVQ>? Mn3GV2FPT0WU
RXF393 NXzre5BZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwOUG0JI5O Mkj6V2FPT0WU
IST-MEL1 MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwOUG3JI5O NXf5ZXU2W0GQR1XS
SF268 NFvoRVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfuepFKSzVyPUCuPVI{KG6P Mnz1V2FPT0WU
KALS-1 MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\nTWM2OD1yLkmyOUBvVQ>? M4O1ZnNCVkeHUh?=
HC-1 NID4[mFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17J[WlEPTB;MD65O|Uhdk1? NGPSd5ZUSU6JRWK=
SW872 NW\DfJg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwOUm2JI5O M1LLTnNCVkeHUh?=
PSN1 NX3nbZd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTFwMEGgcm0> M{iyXHNCVkeHUh?=
TE-1 M{XRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TRd2lEPTB;MT6wN{BvVQ>? MYrTRW5ITVJ?
TE-10 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmKwTWM2OD1zLkCzJI5O NH3sdFZUSU6JRWK=
RKO MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmm0TWM2OD1zLkC2JI5O NW\C[mg5W0GQR1XS
LC-2-ad NILG[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXDS|hoUUN3ME2xMlA5KG6P MnjCV2FPT0WU
SK-MM-2 NFrOVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYSx[mJiUUN3ME2xMlA6KG6P M2\ifHNCVkeHUh?=
VA-ES-BJ NWr3UJhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGP4WmVKSzVyPUGuNFkhdk1? MnXaV2FPT0WU
MZ7-mel MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vLRmlEPTB;MT6wPUBvVQ>? NV7xNVdvW0GQR1XS
D-392MG NYmybnRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;TR3lKSzVyPUGuNUBvVQ>? MXvTRW5ITVJ?
CCRF-CEM M{[4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTFwMUOgcm0> NXX5dmdiW0GQR1XS
EM-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\3bGpkUUN3ME2xMlE3KG6P M1rZXnNCVkeHUh?=
HAL-01 M37QSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjvTWM2OD1zLkG4JI5O NYDTN4dZW0GQR1XS
TE-8 NXHSbmNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGf5fFZKSzVyPUGuNVkhdk1? MkDVV2FPT0WU
NCI-H1882 NXO5PG9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfjcZlTUUN3ME2xMlIhdk1? MlHjV2FPT0WU
Daudi M2\mO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXnUFB{UUN3ME2xMlIzKG6P M1LmfnNCVkeHUh?=
BL-41 NE\X[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXlTWM2OD1zLkK1JI5O MUfTRW5ITVJ?
SR MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWO5RY03UUN3ME2xMlI2KG6P NGXNbINUSU6JRWK=
KM12 MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{W3cWlEPTB;MT6yO{BvVQ>? M1nqWHNCVkeHUh?=
K5 NHPT[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;QNmlEPTB;MT6yPEBvVQ>? MWnTRW5ITVJ?
A3-KAW NFrNfHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HVN2lEPTB;MT6yPEBvVQ>? MU\TRW5ITVJ?
CMK MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTFwMkmgcm0> NWX4N5VtW0GQR1XS
Calu-6 NGXofoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH72bFFKSzVyPUGuNlkhdk1? M3;zd3NCVkeHUh?=
IST-SL2 NV3CW2tHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH0[HNLUUN3ME2xMlMyKG6P NUnMTmk2W0GQR1XS
OPM-2 Ml3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nU[WlEPTB;MT6zN{BvVQ>? MVXTRW5ITVJ?
DU-4475 NVHI[odDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LBVGlEPTB;MT6zOkBvVQ>? MlvZV2FPT0WU
ECC12 M2rUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1THb2lEPTB;MT6zO{BvVQ>? MnvkV2FPT0WU
L-540 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVSxSmw5UUN3ME2xMlM4KG6P M{T3NnNCVkeHUh?=
CAS-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFwM{egcm0> MXLTRW5ITVJ?
PF-382 MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjMXJNKSzVyPUGuOFchdk1? MYnTRW5ITVJ?
LS-411N NFLWS29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfGcJJpUUN3ME2xMlU{KG6P NXfWXXBRW0GQR1XS
NCI-H69 M2\HTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlewTWM2OD1zLkW0JI5O MX;TRW5ITVJ?
NB12 MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3uV2txUUN3ME2xMlU3KG6P NELz[WtUSU6JRWK=
HEL Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1u3OWlEPTB;MT62NUBvVQ>? NGi0e2ZUSU6JRWK=
GCIY MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vBOGlEPTB;MT62NkBvVQ>? M3vYcHNCVkeHUh?=
EHEB MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f1fGlEPTB;MT62O{BvVQ>? MkexV2FPT0WU
TGBC1TKB NXfMPXlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7nSmhKSzVyPUGuO|Ehdk1? M2myV3NCVkeHUh?=
KURAMOCHI NF\oOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH5TWM2OD1zLkeyJI5O NFG3UVhUSU6JRWK=
U-266 NULkRVdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr6cIc{UUN3ME2xMlc3KG6P NVLIdIxEW0GQR1XS
LC4-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTFwN{mgcm0> MkH1V2FPT0WU
NCI-H2126 MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrUTWM2OD1zLkigcm0> NYnLbGNQW0GQR1XS
NCI-H1092 NEDsZW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4f3N2lEPTB;MT64JI5O Mm\wV2FPT0WU
GB-1 NYTiUpNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIn0Z3VKSzVyPUGuPFEhdk1? NILETGJUSU6JRWK=
MV-4-11 M1fLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYH3SZRmUUN3ME2xMlgzKG6P NI\BbmpUSU6JRWK=
Becker NF3sXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFwOEOgcm0> M2TUNHNCVkeHUh?=
MPP-89 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:0emlEPTB;MT64PUBvVQ>? NEPje2dUSU6JRWK=
BE-13 M1vTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XSdmlEPTB;MT65N{BvVQ>? NW[5Zpl[W0GQR1XS
697 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;HTWM2OD1zLkm5JI5O NX;tZY5PW0GQR1XS
NKM-1 NFjaZ5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPYbnZKSzVyPUKgcm0> NFjhR3RUSU6JRWK=
NB13 NX\LXXhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILkbXJKSzVyPUKgcm0> MkixV2FPT0WU
LS-123 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfic5RKSzVyPUKuNFIhdk1? MkT0V2FPT0WU
NB17 NGnZfW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJwMESgcm0> M1\2UnNCVkeHUh?=
LAN-6 Ml[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJwMEWgcm0> MYnTRW5ITVJ?
EW-24 NHTKW5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrERZY1UUN3ME2yMlA5KG6P NInicVRUSU6JRWK=
NOS-1 NXPmWIVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJwMUGgcm0> NVvF[FY3W0GQR1XS
BL-70 MljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzhR2tUUUN3ME2yMlEzKG6P MUXTRW5ITVJ?
GT3TKB M4TTPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFGzRlRKSzVyPUKuNVIhdk1? NWHjXJBWW0GQR1XS
HH NF\4d5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2H2bGlEPTB;Mj6xN{BvVQ>? M2\ZWnNCVkeHUh?=
KE-37 M4rlUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJwMUOgcm0> M3\tTHNCVkeHUh?=
MOLT-4 NVHLPGRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHvPJRZUUN3ME2yMlE{KG6P NEDZWlhUSU6JRWK=
EKVX MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJwMUSgcm0> NXPzWWl{W0GQR1XS
KGN M3e4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:2XmtKSzVyPUKuNVUhdk1? NYfSZ|Z2W0GQR1XS
ES4 M4LKbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjnVIZ7UUN3ME2yMlE3KG6P Mmj3V2FPT0WU
SJSA-1 NYnEOnh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;TTWlEPTB;Mj6yNUBvVQ>? NV3BOZFPW0GQR1XS
KMOE-2 NGHvdFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlG0TWM2OD1{LkKzJI5O MmPPV2FPT0WU
NB5 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJwMkegcm0> NYfHZ2ExW0GQR1XS
BC-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJwM{Ggcm0> NGH4NGpUSU6JRWK=
NB10 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vqTWlEPTB;Mj6zNkBvVQ>? MV7TRW5ITVJ?
RPMI-8226 NYPub2hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LIdmlEPTB;Mj6zOUBvVQ>? MUfTRW5ITVJ?
SCC-3 NYKwUYZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJwM{egcm0> MXzTRW5ITVJ?
ARH-77 M3rj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnSdFlKSzVyPUKuN|ghdk1? MXfTRW5ITVJ?
NCI-H748 NHzZbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nW[2lEPTB;Mj6zPUBvVQ>? Mk[4V2FPT0WU
KU812 NH7xUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHPW3VnUUN3ME2yMlQzKG6P MknDV2FPT0WU
NCI-H64 Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7OTWM2OD1{LkS0JI5O NUn5bIsyW0GQR1XS
NB69 NITzNGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfnTWM2OD1{LkS2JI5O MX7TRW5ITVJ?
KNS-81-FD MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfsTWM2OD1{LkS4JI5O Ml7MV2FPT0WU
LB1047-RCC NY\QVlZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJwNUegcm0> NXPqeoltW0GQR1XS
EB-3 M2T4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVWydJJbUUN3ME2yMlY3KG6P MVvTRW5ITVJ?
Mo-T NVLGNYw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LDbGlEPTB;Mj63OEBvVQ>? M{SzcXNCVkeHUh?=
EW-16 NWHiWo97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVe1cmtHUUN3ME2yMlc2KG6P M4LvUHNCVkeHUh?=
CTV-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mli0TWM2OD1{Lkigcm0> Mnv1V2FPT0WU
ETK-1 NGLxT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlu5TWM2OD1{Lki0JI5O Ml3jV2FPT0WU
C2BBe1 NUTDT4RNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDFTGNKSzVyPUKuPFkhdk1? NV;ybm9GW0GQR1XS
MOLT-16 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LzfGlEPTB;Mj64PUBvVQ>? M4HGXXNCVkeHUh?=
SW954 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7WfmZ7UUN3ME2yMlkhdk1? MVLTRW5ITVJ?
HT NXnlUFNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXO3[opnUUN3ME2zMlAzKG6P NF;xdHBUSU6JRWK=
KARPAS-299 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NESw[pBKSzVyPUOuNFYhdk1? NI\F[3NUSU6JRWK=
MONO-MAC-6 NEHkbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTNwMTDuUS=> NV6we49VW0GQR1XS
CGTH-W-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUP6eVF1UUN3ME2zMlEhdk1? MVHTRW5ITVJ?
SK-PN-DW NH7iXmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLyRpNKSzVyPUOuNVQhdk1? M2nwVXNCVkeHUh?=
CW-2 NGjMcZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXm4WmQxUUN3ME2zMlIyKG6P MmnsV2FPT0WU
SK-N-DZ M3zGbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\wTWM2OD1|LkK2JI5O NEXXOlhUSU6JRWK=
NEC8 NGTsS29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7qTWM2OD1|LkO1JI5O M{HRfnNCVkeHUh?=
LB996-RCC MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfxdXZ6UUN3ME2zMlQhdk1? NWn4bJlyW0GQR1XS
DB M1\wSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTNwNEGgcm0> NVLHWWUzW0GQR1XS
TE-15 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrJSHpNUUN3ME2zMlQ{KG6P MV\TRW5ITVJ?
COR-L88 NVLKWJRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTNwNEegcm0> MmnIV2FPT0WU
LAMA-84 NIXrR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH2OY1KSzVyPUOuOFkhdk1? M2jHSXNCVkeHUh?=
MEG-01 NX:weJF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[3TWM2OD1|LkS5JI5O NVe1dFhCW0GQR1XS
LOXIMVI NXPFZ5ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37w[mlEPTB;Mz61JI5O NWHVbHZDW0GQR1XS
RPMI-8402 M1vxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTNwNTDuUS=> Ml3yV2FPT0WU
KARPAS-45 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe4WG16UUN3ME2zMlU1KG6P MVrTRW5ITVJ?
HCC1187 NGH5fpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD6TWM2OD1|LkW0JI5O MnvEV2FPT0WU
MZ1-PC NI\LNlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1W0NGlEPTB;Mz61OEBvVQ>? NXzHRm96W0GQR1XS
no-11 M13JdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\pbGlKSzVyPUOuOVUhdk1? NU[5UW5[W0GQR1XS
EVSA-T MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD3TWM2OD1|Lk[gcm0> NVXWWm9kW0GQR1XS
DJM-1 MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nuXGlEPTB;Mz62N{BvVQ>? MYHTRW5ITVJ?
COLO-684 MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfqT|dKSzVyPUOuOlYhdk1? NEKxRWFUSU6JRWK=
NMC-G1 MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHxbZhkUUN3ME2zMlY5KG6P NYTXSoFnW0GQR1XS
LC-1F M2nnXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELRVJhKSzVyPUOuO|Qhdk1? M3fIVnNCVkeHUh?=
RL95-2 NWXm[FNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHZTWM2OD1|Lke5JI5O MlO4V2FPT0WU
COLO-320-HSR MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTNwOUKgcm0> M4PuWXNCVkeHUh?=
RCC10RGB NWjZTWljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTNwOUOgcm0> NHTiRYZUSU6JRWK=
HD-MY-Z M1XYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TNOmlEPTB;Mz65N{BvVQ>? NWrBSmE2W0GQR1XS
NCI-H2141 NInWWlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVja[JBDUUN3ME20MlA2KG6P NUKwdIJkW0GQR1XS
K-562 NIjpXlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NImwUpBKSzVyPUSuNVIhdk1? MUfTRW5ITVJ?
NCI-H1648 NV7JXHV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXoVmFDUUN3ME20MlE{KG6P MYPTRW5ITVJ?
OMC-1 M3v5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnuwTWM2OD12LkG4JI5O NXvIfGRnW0GQR1XS
LB647-SCLC NITSdVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTRwMkKgcm0> NGnJN4dUSU6JRWK=
TE-12 M1TmeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fjSGlEPTB;ND6yOUBvVQ>? M3GyVnNCVkeHUh?=
NOMO-1 NH\YSVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4njUWlEPTB;ND6zN{BvVQ>? M{LBenNCVkeHUh?=
Raji M33Lc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3X3ZmlEPTB;ND60OkBvVQ>? NH32VlNUSU6JRWK=
NALM-6 NVfmSHg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L1V2lEPTB;ND60PUBvVQ>? MnPxV2FPT0WU
HL-60 MlHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj2UIFKSzVyPUSuOlchdk1? Mnr3V2FPT0WU
IST-SL1 M1nvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjtN4pKSzVyPUSuOlghdk1? MUDTRW5ITVJ?
MHH-PREB-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjJUYZKSzVyPUSuPFYhdk1? NVzUSlVQW0GQR1XS
MHH-NB-11 NVPXV4RvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfaWndRUUN3ME20MlkyKG6P MVLTRW5ITVJ?
JiyoyeP-2003 MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTVibl2= MXfTRW5ITVJ?
SBC-1 NHrDNFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHU[mNKSzVyPUWuNFEhdk1? NGr3cnpUSU6JRWK=
CHP-126 NV;2OnFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTVwME[gcm0> M{HCU3NCVkeHUh?=
LU-139 M2PTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjLXmM3UUN3ME21MlE{KG6P Mki5V2FPT0WU
NCI-SNU-5 MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\UW2lEPTB;NT6xO{BvVQ>? NHPMSZZUSU6JRWK=
SW962 NV;yVnllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLieZlKSzVyPUWuNlEhdk1? NFzKPVJUSU6JRWK=
EW-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLMOYFKSzVyPUWuN|Ehdk1? NWXsO|Y5W0GQR1XS
NCI-H1417 Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\iTlFKSzVyPUWuOVEhdk1? MUfTRW5ITVJ?
LU-65 NUHHUJF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTVwOESgcm0> NH3xcW9USU6JRWK=
D-502MG M17L[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;aTWM2OD14LkO3JI5O NVKwNG1YW0GQR1XS
BC-3 NEj4OJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4D3cGlEPTB;Nj62NUBvVQ>? Mn30V2FPT0WU
GDM-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTZwN{egcm0> MkLUV2FPT0WU
NCI-H2196 M2nMTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWiwTJM3UUN3ME22Mlghdk1? Ml;jV2FPT0WU
NB1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mme4TWM2OD14Lki4JI5O MUPTRW5ITVJ?
NCI-H345 NY\uenY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL3cZdKSzVyPUeuNkBvVQ>? MWfTRW5ITVJ?
SU-DHL-1 NGW5NWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\wTWM2OD15LkK0JI5O NUjjPW5wW0GQR1XS
JVM-2 NGLDVZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPtTWM2OD15LkK4JI5O NGHTeFlUSU6JRWK=
LU-134-A MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVuzfHNvUUN3ME23MlM6KG6P MmP0V2FPT0WU
NCI-H1694 NVjBRodST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXxNVVKSzVyPUeuOVghdk1? Mor1V2FPT0WU
NCI-SNU-16 NGHJVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTdwNkWgcm0> NH;QXFJUSU6JRWK=
L-363 Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nmRmlEPTB;Nz63JI5O NF6xU4NUSU6JRWK=
KG-1 NFX0NG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlryTWM2OD15Lkm0JI5O MW\TRW5ITVJ?
MN-60 MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRThwMUSgcm0> NWDPSWJOW0GQR1XS
NB6 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3u0PWlEPTB;OD60PEBvVQ>? NXS3O4JYW0GQR1XS
MLMA NGHpeJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLITWM2OD16Lki1JI5O NGTBdVlUSU6JRWK=
ATN-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRThwOEmgcm0> MkPOV2FPT0WU
SK-NEP-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP6b2pKSzVyPUmuNFEhdk1? M{KxR3NCVkeHUh?=
DMS-114 M{LKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGiyS3BKSzVyPUmuOlIhdk1? NWOzXlN1W0GQR1XS
CTB-1 NXzDdYxwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP6[lZKSzVyPUmuOlchdk1? MUXTRW5ITVJ?
NCI-H2081 M{DUW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTFyLkC5JI5O MlLZV2FPT0WU
ES5 NV7XSGVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\ie|ZKSzVyPUGwMlM5KG6P MWPTRW5ITVJ?
HCC1599 MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmGyTWM2OD1zMT65NUBvVQ>? NI\SSY9USU6JRWK=
NCI-H23 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4i5V2lEPTB;MUKuNVIhdk1? MULTRW5ITVJ?
NCI-H1581 NXnhNlExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TWZWlEPTB;MUKuNlghdk1? MnjzV2FPT0WU
JVM-3 NVv1RldST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPNTWM2OD1zMj65PUBvVQ>? M1exdXNCVkeHUh?=
NCI-SNU-1 NVHxVIkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPzPVVKSzVyPUGzMlE6KG6P M3T2Z3NCVkeHUh?=
NB7 M171W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVuwbJFuUUN3ME2xOU46OiCwTR?= MVXTRW5ITVJ?
JAR NX;KfHJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTF4LkGzJI5O M4Hj[XNCVkeHUh?=
TGW MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjFS2RKSzVyPUG2MlQ5KG6P MmTOV2FPT0WU
U-87-MG M2nFbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvFSJVJUUN3ME2xOk44PiCwTR?= NV\xXIl[W0GQR1XS
NCI-H1436 Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvkemI3UUN3ME2xO{4xOSCwTR?= NGHVOm1USU6JRWK=
GOTO M1frTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLlTWM2OD1zNz6wOkBvVQ>? NGDjdI9USU6JRWK=
COLO-800 NXLGdWhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGP5Z4JKSzVyPUG3MlY1KG6P M4i4RXNCVkeHUh?=
MFM-223 NUnmRmdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moi3TWM2OD1zNz65NUBvVQ>? M{DlV3NCVkeHUh?=
EW-18 M2\M[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXqzfXh4UUN3ME2xO{46PiCwTR?= NHLTfVNUSU6JRWK=
NB14 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;VNpBKSzVyPUG3Mlk5KG6P NFTZb|lUSU6JRWK=
EB2 NIPIW4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTF6LkC4JI5O MlKwV2FPT0WU
EoL-1- NUTBUFVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHaXWp4UUN3ME2xPE4{OSCwTR?= MXjTRW5ITVJ?
NCCIT M1zxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHS[JZLUUN3ME2xPE4{PiCwTR?= NHHEfVdUSU6JRWK=
DG-75 M2nh[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\yTWM2OD1zOD62NUBvVQ>? NWDqWno1W0GQR1XS
HCC2218 NX;5bopZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTF7LkWgcm0> NHX0c|JUSU6JRWK=
TE-6 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2P6PGlEPTB;MkCuNFghdk1? MnT0V2FPT0WU
SF539 NEWyWXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL6NZB3UUN3ME2yNE43PyCwTR?= NYrFTYZKW0GQR1XS
NCI-H446 Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrSSHRKSzVyPUKxMlE5KG6P NX\Bco12W0GQR1XS
IST-MES1 MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jSNWlEPTB;MkKuO|chdk1? M2Tq[nNCVkeHUh?=
NCI-H82 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonCTWM2OD1{Mz6wNkBvVQ>? MkTQV2FPT0WU
HCC2157 NGi4[29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGG3VplKSzVyPUKzMlE{KG6P Mmf3V2FPT0WU
EW-12 NYDkbZloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\FcWtSUUN3ME2yN{4yPyCwTR?= M4XZO3NCVkeHUh?=
SIMA Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1q4O2lEPTB;MkOuN|ghdk1? MnjoV2FPT0WU
DOHH-2 Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlX0TWM2OD1{Mz60OUBvVQ>? NFPCSJpUSU6JRWK=
IM-9 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnDeGdiUUN3ME2yN{42PCCwTR?= M3PMZ3NCVkeHUh?=
EC-GI-10 NIn4dHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHzTWM2OD1{ND6yN{BvVQ>? MlvwV2FPT0WU
HDLM-2 M2K0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLXTWM2OD1{ND61OEBvVQ>? Mlv2V2FPT0WU
LS-1034 M2PjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXhZpdWUUN3ME2yOU44PSCwTR?= MlnkV2FPT0WU
REH MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHmwNGxKSzVyPUK2MlQyKG6P MmH6V2FPT0WU
LU-165 M4HLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJ4LkeyJI5O MXTTRW5ITVJ?
NH-12 MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjBfZV5UUN3ME2yO{43PyCwTR?= NIS3WYlUSU6JRWK=
WSU-NHL MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XFO2lEPTB;MkiuN|khdk1? M2W5XHNCVkeHUh?=
ECC4 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rvOWlEPTB;MkiuO|khdk1? MkjlV2FPT0WU
OCI-AML2 NYHrN4J{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJ7Lk[5JI5O NGLlVpFUSU6JRWK=
EW-3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTNyLkW5JI5O Mo\YV2FPT0WU
NCI-H526 MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjNTWM2OD1|Mj61OEBvVQ>? MlHxV2FPT0WU
NCI-H719 NH;p[|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[2TWM2OD1|ND6zNUBvVQ>? MUXTRW5ITVJ?
KARPAS-422 MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTN3LkC0JI5O NX\lTZNRW0GQR1XS
SK-MEL-1 NEXCbYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTN3LkG3JI5O MoniV2FPT0WU
ES3 NIPtTIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{m0XWlEPTB;M{WuNVkhdk1? M1PPZ3NCVkeHUh?=
UACC-812 MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mor4TWM2OD1|NT60OEBvVQ>? NHPqXJdUSU6JRWK=
C8166 NIDrOpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrnTWM2OD1|NT63JI5O NW\zN5hxW0GQR1XS
MDA-MB-134-VI MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInoS5BKSzVyPUO1Mlg4KG6P NHvEbIVUSU6JRWK=
D-283MED MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DKcWlEPTB;M{euO|khdk1? M{\ZNHNCVkeHUh?=
SHP-77 M2rJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVq0WlQ4UUN3ME2zPE4xOyCwTR?= M120fnNCVkeHUh?=
NCI-H2227 M2XTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHC[mMyUUN3ME20NE41QSCwTR?= NGP3XIlUSU6JRWK=
SKM-1 NGLjeFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLSUGlsUUN3ME20Nk43OyCwTR?= M{\j[HNCVkeHUh?=
L-428 NH73dpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonCTWM2OD12Mz64OkBvVQ>? M2C0N3NCVkeHUh?=
RPMI-6666 M{XNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjPdnVZUUN3ME20OU45QSCwTR?= NY\SOHRiW0GQR1XS
NCI-H716 M3zqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L5SmlEPTB;NEiuPFEhdk1? NGrMNJlUSU6JRWK=
DMS-79 M4\RUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LT[WlEPTB;NUCuO|Ehdk1? NV7rZoc1W0GQR1XS
RS4-11 NWPROI1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XSWGlEPTB;NUCuPFghdk1? Ml7nV2FPT0WU
NCI-H720 M3KyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXN[mtKSzVyPUWxMlEyKG6P NHHXNWxUSU6JRWK=
MC-CAR MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjzTWM2OD13MT61NkBvVQ>? NHjEdIhUSU6JRWK=
TALL-1 M4L5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTV|LkmxJI5O Mo\6V2FPT0WU
NCI-N87 NXjjRnRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHJNXpnUUN3ME21OE4yQCCwTR?= M3;yZnNCVkeHUh?=
P30-OHK NWHRZWRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u1W2lEPTB;NUSuOlEhdk1? MUnTRW5ITVJ?
LP-1 M4nCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\DW|dKSzVyPU[xMlI5KG6P MlHXV2FPT0WU
YT NFnRPG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PiN2lEPTB;NkGuPEBvVQ>? NIDD[GhUSU6JRWK=
MRK-nu-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTZzLkiyJI5O NH;CS4ZUSU6JRWK=
BT-474 NWjWVm56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jhSGlEPTB;NkWgcm0> MV\TRW5ITVJ?
NCI-H322M MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTZ4LkGxJI5O M1HsUHNCVkeHUh?=
NCI-H128 NEHLd|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;6R3JlUUN3ME23OE44PyCwTR?= MUHTRW5ITVJ?
KMS-12-PE MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TSUGlEPTB;N{[uNlQhdk1? M4nQSnNCVkeHUh?=
KP-N-YS M3uzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETobW1KSzVyPUe2Mlc1KG6P NGrtbohUSU6JRWK=
ALL-PO M2DZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTd5Lk[2JI5O M4GxNXNCVkeHUh?=
EW-13 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjMNoVuUUN3ME23O{44PiCwTR?= MVnTRW5ITVJ?
EW-11 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7rT3FIUUN3ME23PE42OiCwTR?= M2rLeHNCVkeHUh?=
SK-N-FI NYXvXo9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknTTWM2OD16MD6yJI5O NIHNWYdUSU6JRWK=
CAL-148 Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRThzLki0JI5O M1vKdnNCVkeHUh?=
RL M1HUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTh4LkC5JI5O MXHTRW5ITVJ?
AM-38 M4nIWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWr3WmVlUUN3ME24PE4xQCCwTR?= NFWyOnZUSU6JRWK=
RH-1 NY\GO2xjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWiye5gyUUN3ME25PU45PSCwTR?= NF35ZYJUSU6JRWK=
NCI-H1770 NVvEUlhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHFbHFwUUN3ME2xNFIvPDlibl2= MWjTRW5ITVJ?
SIG-M5 MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmX1TWM2OD1zMEWuNFYhdk1? NGX4O41USU6JRWK=
GR-ST NE\uNY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorFTWM2OD1zMUOuN|Qhdk1? M3nLN3NCVkeHUh?=
ST486 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7nc4dKSzVyPUGxOE4xPiCwTR?= NYrRNJBvW0GQR1XS
NCI-H1650 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\qfIp{UUN3ME2xNVUvOjlibl2= NUPLSYdmW0GQR1XS
MHH-CALL-2 M1\iVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDJV|RKSzVyPUGxOU44KG6P NYD6PZFIW0GQR1XS
BV-173 MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPG[XpUUUN3ME2xNlIvPzFibl2= NYLkcnpDW0GQR1XS
MC116 M{fLPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HpZWlEPTB;MUS4Mlg2KG6P M1v1dXNCVkeHUh?=
NCI-H524 M2P2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHVepVKSzVyPUG1PU4yKG6P M1LTTnNCVkeHUh?=
SCLC-21H MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH73b4FKSzVyPUG1PU41OSCwTR?= MmK3V2FPT0WU
NCI-H1304 NWn6TZB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXxTWM2OD1zNkmuNlEhdk1? NFPveVBUSU6JRWK=
NCI-H510A M1;jXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnj0TWM2OD1zOEWuN|chdk1? M3z2eXNCVkeHUh?=
NCI-H209 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXoSWpkUUN3ME2xPVYvPTJibl2= NYXSW5lvW0GQR1XS
KM-H2 NY\RWIpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1P3XGlEPTB;MUm3MlA2KG6P NUfje5hrW0GQR1XS
NCI-H1395 M3zXfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnob2N6UUN3ME2yNVAvOTNibl2= M2f3THNCVkeHUh?=
NCI-H1155 NFfQNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2i2U2lEPTB;MkOwMlMzKG6P M4PUZnNCVkeHUh?=
COR-L279 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXP1XFNVUUN3ME2yOVIvOTdibl2= MnTkV2FPT0WU
NCI-H1299 M2SzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTNRYtKSzVyPUK2NU44OSCwTR?= Ml;UV2FPT0WU
EW-22 Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\aSWlEPTB;Mk[zMlc2KG6P MVHTRW5ITVJ?
SK-MEL-2 M1PNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJ6MT65JI5O NUX1SWNKW0GQR1XS
KASUMI-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTJ6Mz6wOUBvVQ>? NYCwZ5RtW0GQR1XS
NCI-H187 NFjyTYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJ6Nz6wPEBvVQ>? M1;GcnNCVkeHUh?=
NCI-H2171 MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHmVJZTUUN3ME2yPFgvQTJibl2= MX\TRW5ITVJ?
LNCaP-Clone-FGC M4DW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jxT2lEPTB;Mkm1MlI3KG6P NEnMV4pUSU6JRWK=
NCI-H1522 M{nucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nTTmlEPTB;M{C3MlA2KG6P MkXTV2FPT0WU
SCH NIC2TG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3zOotHUUN3ME2zNlIvOjJibl2= M4T6[XNCVkeHUh?=
THP-1 NHjjT2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTX[XVKSzVyPUOyNk43KG6P M1z3XHNCVkeHUh?=
SNU-C1 M2jMN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7PSZN6UUN3ME2zOlIvODlibl2= MmDUV2FPT0WU
CA46 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHj5PIlKSzVyPUO3N{43OyCwTR?= NEjsS2hUSU6JRWK=
NCI-H1963 NX;FXW43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTN6Nj6xPUBvVQ>? NInYe41USU6JRWK=
DEL NFXlR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmftTWM2OD1|OUGuNlchdk1? NF;KNVBUSU6JRWK=
TUR NFPjblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PhcWlEPTB;M{m2MlYyKG6P MkDGV2FPT0WU
NCI-H226 M4PQNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjxTWM2OD12MEOuNlMhdk1? MV\TRW5ITVJ?
COLO-668 M2Lre2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDlWVdDUUN3ME20NFMvPTdibl2= M{XsfnNCVkeHUh?=
CPC-N MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTRyMz63O{BvVQ>? NHrUd2tUSU6JRWK=
NCI-H889 MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLhTWM2OD12NkGuPVIhdk1? M17QbnNCVkeHUh?=
J-RT3-T3-5 NEL0eJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;pO5lKSzVyPUWzNk42PyCwTR?= M1[5XXNCVkeHUh?=
MSTO-211H NX;WdJp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvBfodKSzVyPUW3OE4zPiCwTR?= NYfn[ZZHW0GQR1XS
SCC-15 NX;u[2E3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTZ4Nz60O{BvVQ>? M3y5[HNCVkeHUh?=
SUP-T1 NX3lSHV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;CdWhKSzVyPU[4Ok4xPCCwTR?= MlroV2FPT0WU
DMS-153 M2LEb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHoTWM2OD15NE[uPFMhdk1? NWO3e5p4W0GQR1XS
MS-1 M{TtVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;RTWM2OD15NUmuOFIhdk1? MYXTRW5ITVJ?
TC-YIK NXHlZldlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\wTWM2OD15OEGuNFEhdk1? NEXVcYtUSU6JRWK=
RPMI-8866 NFjLeXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTFyME[uNlgh|ryP NHPHXm1USU6JRWK=
KY821 NX\0eGVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnvTWM2OD1zMEO2MlA1KM7:TR?= MVrTRW5ITVJ?
P31-FUJ NF7SPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTFzMUKuO|Uh|ryP NX[zXYJpW0GQR1XS
COLO-824 NUTM[GxlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTlbZdKSzVyPUGyOlEvPzhizszN NHTpRYZUSU6JRWK=
U-698-M NEDENGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkj3TWM2OD1{Mk[yMlE2KM7:TR?= MUjTRW5ITVJ?
TE-441-T NIP4fnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJ3MkGuO{DPxE1? M4PKdnNCVkeHUh?=
IMR-5 NIjYfHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfKOnBKSzVyPUO0NFkvPjJizszN MXHTRW5ITVJ?
NCI-H1838 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTRzOE[uN|Ih|ryP NIjyR5RUSU6JRWK=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
phospho-PERK / ATF-4; 

PubMed: 15509775     


UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against phospho-PERK, ATF-4. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. 

GRP-78 / GADD-34; 

PubMed: 15509775     


UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against GRP-78, and GADD-34. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. 

pro-caspase-12 / pro-caspase-3; 

PubMed: 15509775     


MEFs were treated with PS-341 for the indicated time periods, and the whole-cell extracts were prepared. Fifty-microgram aliquots of proteins were probed with polyclonal antibodies against caspase 12 and caspase 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin. 

pro-caspase-9; 

PubMed: 15509775     


UMSCC-23 cells were pretreated with or without Tiron for 30 min and then treated with PS-341 for the indicated time periods. The whole-cell proteins were probed with polyclonal antibodies against caspases 9 and 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin.

p-IκBα / IκBα; 

PubMed: 20335171     


PS-341 induces IκBα degradation in human lung cancer cells. The given cells lines were treated with the indicated concentrations of PS-341 for 8 h (C). After treatment, the cells were then subjected to preparation of whole-cell protein lysates and subsequent Western blot analysis. 

COX-2 / cIAP2; 

PubMed: 24085292     


NCI-H157 cells were incubated with PS-341 (50 nM) or MG132 (20 μM) for the indicated times.  Total cellular extracts were subjected to Western blot analysis for COX-2, cIAP2 and actin. 

15509775 20335171 24085292
Immunofluorescence
Vimentin; 

PubMed: 19010849     


ES-2 ovarian cancer cells were incubated with 5nM PS-341, 10 μM NK84 or the combination of both for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). 

Ubiquitin; 

PubMed: 19010849     


IOSE-29 cells were incubated with 20nM PS-341 for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). 

19010849
Growth inhibition assay
Cell viability ; 

PubMed: 20571067     


A, TSA enhanced the cell death induced by PS-341 in UMSCC1 cells. Cell viability was determined by the trypan blue exclusion assay. The assays were performed with triplicate samples, and the results are representative of three independent experiments (**P < 0.01). Error bars depict standard deviation. B, C and D, TSA enhanced PS-341-induced cell death in UMSCC23 (B), UMSCC9 (C), and FaDu (D). **P < 0.01.

20571067
ELISA
IL-8; 

PubMed: 24085292     


NCI-H157 cells were treated with PS-341 (10–100 nm) or TNF-α (10 ng/ml) as a positive control for 24 h. IL-8 concentrations in media were determined by ELISA. Data represent the mean ± S.D. of triplicates. **, p < 0.05 versus control cells. Results are representative of three separate experiments.

24085292
In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]
- Collapse

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]
- Collapse
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]
- Collapse
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4
CAS No. 179324-69-7
Storage powder
in solvent
Synonyms LDP-341, MLM341
Smiles CC(C)CC(NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03993262 Not yet recruiting Drug: Bortezomib|Drug: Placebo Autoimmune Encephalitis Jena University Hospital February 1 2020 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • Answer:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

selleck catalog

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

  • Pan Proteasome Inhibitor

    Ixazomib (MLN2238) : β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.

  • FDA-approved Proteasome Inhibitor

    Carfilzomib (PR-171) : Approved by FDA for multiple myeloma.

  • Newest Proteasome Inhibitor

    Oprozomib (ONX 0912) : Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

Related Proteasome Products

  • VR23 New

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin New

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat (BB-2516) New

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • MG-132

    MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • Ixazomib Citrate (MLN9708)

    Ixazomib Citrate (MLN9708) immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Tags: buy Bortezomib|Bortezomib ic50|Bortezomib price|Bortezomib cost|Bortezomib solubility dmso|Bortezomib purchase|Bortezomib manufacturer|Bortezomib research buy|Bortezomib order|Bortezomib mouse|Bortezomib chemical structure|Bortezomib mw|Bortezomib molecular weight|Bortezomib datasheet|Bortezomib supplier|Bortezomib in vitro|Bortezomib cell line|Bortezomib concentration|Bortezomib nmr|Bortezomib in vivo|Bortezomib clinical trial|Bortezomib inhibitor|Bortezomib Proteases inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID